Introduction
The genetic basis for oncogenesis received strong experimental support some 20 years ago and the discovery of avian defective retroviruses carrying oncogenes has provided one of the first demonstrations for it. It is now acknowledged that an oncogene dominantly transforms a normal cell. The last 10 years have been characterized by an astonishing and exciting continuous explosion of information on genetic lesions associated with human tumors, particularly leukemias and lymphomas. The relevance of such data from the diagnostic, prognostic and now therapeutic points of view is no longer in question. Interestingly, in the majority of cases altered genes are transcription factors, either fused into new chimeric proteins or deregulated in their expression. The fact that many of the classically defined oncogenes have been subsequently found to be transcription factors, together with the above considerations, has led to the generalized and now widely accepted concept that transcription factors can easily become oncogenes. It is our opinion that this conclusion is probably true, but the molecular mechanisms which render a transcription factor oncogenic in a determined cell type are still obscure and we therefore still lack crucial molecular targets, for example for therapeutic intervention.
We will take the opportunity to critically reconsider the work of others, as well as our own, on one such oncogene, myb, which has been amongst the first to be isolated. For this reason we will not discuss published work on characterization of functional domains of the myb genes, the deduced three dimensional structure of the DNA binding motif, or the cloning and functional characterization of myb-related genes from lower eukaryotes or plants, and other aspects which do not appear to be directly connected with the biological transforming capacity of the oncogenes. 
The avian v-myb oncogenes
The chicken system was instrumental for the identification of the myb oncogene since two retroviruses were isolated which acutely induce leukemia and were subsequently found to contain two versions of the same gene: the E26 virus carries the p135 Gag-Myb-Ets fusion protein and the avian myeloblastosis virus (AMV) encodes the p45 v-Myb protein only. In both cases the Myb protein had suffered N-terminal truncations of one of the three imperfect repeats which characterize its DNA binding domain with respect to the normal c-Myb counterpart, and more severe C-terminal truncations. Furthermore in the E26 virus, v-Myb is fused to a second oncoprotein, Ets, whereas it has suffered 11 point mutations with respect to its cellular counterpart c-Myb in the AMV version.
The E26 virus rapidly induces an erythro-myeloid leukemia in vivo while AMV induces a myeloid leukemia. A crucial step toward the understanding of the biological action of these viruses was the setting up of bone marrow culture protocols in vitro which were instrumental for the identification of the transforming capacity of the two viruses in vitro. E26 infection resulted in growth of myeloid and erythroid colonies, AMV infection only myeloid. So, there was a satisfying correlation between the in vitro and the in vivo phenotype which has been described in a well known series of papers (for reviews see Refs 1-3).
Plasticity of hematopoietic differentiation
More recently, it has become clear that changing the target of the in vitro infection could lead to a different phenotype of the transformed cells. In particular, infecting 2-day-old chick blastoderm cells (probably containing multipotent hematopoietic progenitors derived from the yolk sac), the E26 virus transforms cells which can be induced to differentiate into erythrocytes, thrombocytes, myeloblasts, eosinophils and have been termed MEPs for Myb-Ets transformed progenitors, and may resemble murine CRU-Mix. 4 The elegant subsequent work with temperature sensitive (ts) mutants on both oncogenes, has further allowed the transforming activity for the myeloid and thrombocytic lineages to be attributed to the myb oncogene, 5 whereas the erythroid and eosinophilic differentiation block was mainly due to the ets oncogene. 6, 7 Even the previous observations on the mixed erythroid/myeloid colonies obtained from the bone marrow infections with E26 could be reconciled with these data by showing the monoclonality of the cells and therefore their derivation from the same transformed multipotent progenitor.
Finally, one important contribution came from the observations that the fusion protein Myb-Ets was necessary for in vivo leukemogenicity, in that retroviruses encoding separate Myb and Ets proteins in the same genome could not induce leukemias. 8 This crucial observation should always be considered when evaluating the role of the two partners in other cases of oncogenic fusion proteins present in human translocations. Additionally, in this particular example, both the DNA binding domain (of Myb and Ets) and the Myb transactivation domain were necessary when present on the same molecule.
On the other hand, v-Myb from AMV transforms relatively mature myeloid precursors, and not earlier progenitors. Interestingly, work on single point mutants in its DNA binding domain demonstrated that either granulocytic or monocytic precursors could be obtained in vitro or in vivo. 9 These data suggest that Myb itself may have the capacity to direct hematopoetic differentiation towards one rather than another lineage (granulocytes vs monocytes).
To summarize what has been learnt from this unique and versatile system on the oncogenicity of the myb oncogenes, in their in vivo selected versions, Myb proteins can dominantly and acutely cause leukemia in chicks: Myb in the E26 configuration transforms very immature cells, whereas Myb in the AMV configuration transforms late myeloid precursors.
The observations mentioned above suggest that Myb is more 'responsible' for the myeloid-thrombocytic phenotype, while the Ets is more responsible for the erythroid-eosinophilic phenotype. What does this really mean and what is the mechanism for the cell type and differentiation stage specific transformation?
The first point that we can make is that presumably immediately upon infection the viral protein is made and this protein induces a particular phenotype. In which cells does this occur? Are they very early uncommitted progenitors that are pushed downstream by the oncogene and then arrested at a certain stage? Or rather, are they a more heterogeneous population, assuming the oncogene has the capacity to reprogramme a differentiation scheme imposing its own phenotype? Or are they mature cells which are dedifferentiated? We have no sure answer to these crucial questions, but few experiments of superinfection of already transformed cells have suggested the possibility of a strong 'reprogramming' action by at least some oncogenes. 10 Furthermore, these observations may imply that Myb protein works as a 'key master gene' that when overexpressed in a permissive cellular context induces a myelo-thrombocytic phenotype. Which is the genetic cascade of genes which allows the full exploitation of this potential? Do these data support the idea that normal Myb protein can have similar function during hematopoietic differentiation? We have no sure answer for these questions.
Regarding the mechanism of transformation, we also know that certain protein configurations (N and C terminal truncations) are crucial for oncogenicity, while others are not, and that the normal myb proto-oncogenes are certainly not transforming. The molecular basis for this is not clear but may relate to the target genes or to functional partners as discussed below. In particular, the C terminal truncation clearly removes negative regulatory regions on the transactivating function producing a stronger transcription factor. The truncation and/or mutations within the Myb protein may lead to aberrant expression of a set of genes.
We certainly know that the transcription factor activity of the genes is important because mutants with stronger transactivation activity are more transforming and because subtle changes in the DNA binding domain can change their activity dramatically (eg point mutants and ts mutants mentioned above). It may also be that the mechanism is different, perhaps due to the simple presence of the aberrant protein in itself, although no evidence in this sense has been provided.
Oncogenicity of myb in mammalian systems
Interestingly, the first rigorous demonstration that a truncated Myb may have some role in human leukemias has just been published 20 years after its discovery. In a CML patient undergoing T cell blast crisis, in fact, the appearance of truncated c-myb mRNA and of its protein product lacking the Cterminal region has been observed. 11 This truncated c-Myb shows elevated transactivating activity compared with the wild-type protein. The authors document that this mutation was acquired during disease progression and was not present during the early manifestation of disease, suggesting a role during blast transformation. 11 In murine and bovine experimental models, truncated cMyb has been associated with either B or T cell lymphomas either via insertional mutagenesis of retroviruses or through the targeted creation of transgenic mice with deregulated tissue-specific expression of a truncated c-Myb. In both cases the activity of the oncogene is only detectable in a percentage of animals and appears to be a late event probably associated with other yet undefined oncogenic genetic alterations.
Thus the chicken system appears to be rather peculiar in that in this case a single oncogene is sufficient to induce leukemia, whereas in mammals, including man, more than one event seems to be required for leukemogenicity.
The molecular basis for the cell-and stage-specific transformation
Following these seminal observations, therefore, widespread effort has been conducted to characterize the myb target genes, based on the supposition that transcription factors in general, and Myb in particular, transform through deregulated transcription of one or more target genes. The findings reported above that v-Myb or truncated c-Myb are stronger transcription factors than their normal counterpart as well as that transcriptional activity was required for transformation lent support to this hypothesis.
Many potential Myb target genes have been identified. In order to classify and summarize this rather large amount of information, we can say that many of them, but not all, are specific for the hematopoietic compartment. Others are related to the cell cycle and/or apoptosis. Another aspect that has emerged over the last few years is that at least for some target genes, co-operation of Myb with other proteins is crucial for manifestation of full transactivating ability. Thus the Myb and Ets transcription factors together have been demonstrated to functionally co-operate for transcriptional activation of the hematopoietic specific c-fms, 12 25, 26 while together with CBF it regulates myeloperoxidase. 27 Myb and C/EBP synergize to activate transcription of mim-1 in chicken cells (a neutrophil granule protein of the defensin family expressed by avian granulocytes) 28, 29 and tom-1. 30 More problematic for this discussion is the interpretation of the data showing that Myb can transcribe DNA topoisomerase II, 31 adenosine receptor 2B, 32 Wilm's tumor 1 gene, recombination of the TCR has been attributed to Myb in conjunction with CBF for the transcriptional regulation of the enhancer of the TCR-␦ [35] [36] [37] [38] and, less strongly, for the TCR-␥. 39 The chicken mim-1 gene has been the first and best described target for the v-Myb oncoprotein. It was cloned 10 years ago through differential hybridization of myeloblast cells transformed by a temperature-sensitive v-Myb protein from the E26 virus (Myb-Ets). 40 For this gene, there has been ample demonstration of a co-operating role of Myb and C/EBP, possibly through direct interaction of their DNA-binding domains. 28, 29, 41 Interestingly, the AMV v-Myb is the only oncogenic form of Myb protein which does not induce mim-1 transcription. 9 The mim-1 promoter contains binding sites for both myb and the myeloid-specific chicken C/EBP␤ (also called NF-M). 41 Ectopic expression of c-Myb and NF-M in erythroid cells or fibroblasts was sufficient to induce expression of the endogenous mim-1 gene. 29 Recently the homeobox gene GBX2 was cloned and found to be crucial for the transcription of the chicken myelomonocytic growth factor (cMGF). 42 More interestingly, the GBX2 gene itself was found to be a target for AMV v-myb. Also cmyb can activate GBX2 transcription, but only in conjunction with an activated tyrosine kinase signalling pathway. The fact that AMV may constitutively induce GBX2 can be looked at as a gain of function. On the contrary both E26 v-Myb and cMyb can, in co-operation with C/EBP, induce and transcribe mim-1, whereas AMV v-Myb cannot. Thus in this case, the AMV v-Myb mutations lead to a loss of function. These observations open the possibility that the cellular c-Myb protein may control two distinct genetic pathways: one, exemplified by its co-operation with C/EBP and the downstream transcription of mim-1 may be linked to granulocytic differentiation; the other one, through additional external signals, may transcribe GBX2 leading to the production of the growth factor cGMF and to monocytic differentiation. 42 One could argue that E26 v-Myb has maintained the 'granulocytic pathway' of c-Myb, while the AMV mutations have unbalanced the oncoprotein towards 'monocytic differentiation'.
Nonetheless, there still might be targets which are induced by both AMV and E26 v-Myb as exemplified by tom-1. 28 Tom-1 is expressed in AMV and E26 cells but it is expressed much more in skeletal muscle. Also in this case (as for mim-1 and lysozyme) C/EBP is a co-operation partner. All three forms of C/EBP, ␣, ␤, and ␦, can synergize with Myb. Nonetheless, cotransfection experiments in fibroblasts fail to show induction of endogenous tom-1, suggesting that additional signals may yet be required for transcription of this gene. 28 Indeed for only few of the proposed Myb targets is there evidence that the endogenous genes are transcribed in the blasts transformed by the oncogenic Myb: this is the case only for mim-1, tom-1, GBX2 and bcl-2.
The actual target genes that are directly responsible for oncogenic transformation by Myb proteins are still little known. GBX2 it is a particularly interesting candidate for several reasons: (1) v-Myb may activate GBX2 constitutively and in the absence of other signals which would be normally required. (2) GBX2 can itself transactivate the cMGF gene rendering the transformed cells growth factor-independent by an autocrine mechanism. This may be one important although probably not sufficient element for transformation. (3) GBX2 is a homeobox gene. The homeobox family of transcription factors may act as master genes by activating a set of target genes required for a specific developmental pathway. Indeed homeotic genes are target genes of several transcription factors involved in human translocations (reviewed recently in Ref. 43) .
Another observation of particular interest in the context of transformation is that the E26 Myb-Ets protein can prevent chicken myeloblasts from undergoing apoptosis, and can also transactivate the bcl-2 gene. [44] [45] [46] To summarize, although many potential myb targets have been identified, very few appear biologically relevant to the transformation events, but these few allow us to start formulating hypotheses about the mechanism and specificity of transformation.
Other models to dissect the biological function of c-Myb and v-Myb
Important information on the putative mechanism of action of the myb oncogene came from several studies describing stably transfected myeloid or erythroid cell lines. In all cases overexpression of the c-Myb or v-Myb protein led to a 'block' in the differentiation induced by specific signals, or even to dedifferentiation (Ref. 47 and references therein). One possible criticism of these experiments is that the targets were already transformed cells which in addition had undergone stringent selection after transfection. More importantly, no information has yet been obtained from these models about the presumed Myb target genes involved in the 'differentiation reprograming' of the cells.
An important piece of evidence for the role of c-Myb in hematopoiesis has come from the single report on c-myb KO mice. Interestingly, the homozygous mice died in utero at day 15 as a result of severe anemia. While embryonic erythropoiesis was not impaired, adult type erythropoiesis, which takes place in the liver, was greatly diminished. Quite surprisingly, the megakaryocytic lineage seemed unaffected, while other lineages were severely impaired. 48 Again these data suggest that c-Myb activates sets of genes required for some but not all differentiation pathways. More recently, elegant experiments with the c-myb-null embryonic stem (ES) cells showed that c-Myb is not necessary for early CD34 expression since these cells do express CD34 during in vitro differentiation like control cells. Furthermore this last report confirmed that endothelial differentiation is still intact, whereas hematopoietic differentiation does not take place. 49 That c-myb is required for human hematopoiesis has also been confirmed in vitro using anti-c-myb antisense oligonucleotides. 50 One mechanism for this block could be a lack of proliferation of the immature hematopoietic cells in the absence of myb. In contrast to the knock out mice, antisense also inhibited the growth of megakaryocyte colonies. 50 The reason for these differences are not clear.
The role of adaptor proteins and co-factors
It has been known for some time that transcription factors work through the interaction with other proteins, in particular adaptor proteins that bridge them to the general transcription machinery and co-factors that have specific enzymatic activities that allow the opening of chromatin and facilitate the transcription process. It is evident therefore that much effort has been made to identify and characterize molecular partners for the c-Myb and v-Myb proteins, also with the aim of dissecting the mechanism of Myb-induced oncogenesis.
The data so far obtained are still difficult to interpret with 56 and the peptidyl-prolyl isomerase cyp40. 57, 58 Whether the oncogenic activation of c-Myb by mutation or truncation leads to an alteration in the functional interaction with these proteins still needs to be determined.
Also structural analysis of the DNA binding domain has shown that it has a helix-turn-helix motif subsequently found in several other transcription factors. [59] [60] [61] Studies of the v-Myb mutations, several of which are present within the DNA binding domain, has shown that these do not alter dramatically the overall 3-D structure of the domain, although subtle changes in flexibility of the structure have been reported.
Related genes
Other areas have been developed over the last 10 years which are related to the oncogenic role of c-Myb/v-Myb. The first has been the cloning of new genes from animal species, as well as from plants which are structurally related to c-myb/ v-myb. The plant genes are very numerous (over 100 in some species) and are transcription factors sharing significant homology essentially only within the DNA binding domain. Thus the helix-turn-helix structure of the Myb DBD with regularly spaced tryptophan residues has been particularly successful during evolution. 2 The interesting analogy with c-Myb is that plant Mybs also play a crucial regulatory role during plant development. In several animal species, including man, two Myb-related transcription factors, called A-Myb and B-Myb have been identified. 62 Also A-myb is a putative oncogene since the forced expression of the normal A-Myb protein in transgenic mice leads to follicular hyperplasia of B cells 63 in agreement with its restricted expression during normal hematopoiesis within the germinal center B-centroblastic population. [64] [65] [66] [67] Also in this case, hyperplasia is detected late and only in a portion of the animals suggesting that other oncogenic events are required. Although several studies have been published showing that A-Myb is a transcription factor [68] [69] [70] even less is known than for c-Myb about the possible mechanism by which it may deregulate B cell growth and differentiation or about its target genes.
We can conclude that despite much useful work performed in an attempt to define how c-Myb or v-Myb can transform hematopoietic cells, much still remains to be done, particularly regarding the identification of relevant target genes whose deregulated expression may in turn block differentiation, induce a specific differentiation pathway or cause uncontrolled proliferation of the cells. Increasing our knowledge of functional partners for c-Myb/v-Myb acting either as adaptor or co-factors may also help in this sense. Other as yet undiscovered elements of Myb function may also be of importance. Thus the original question asked as to how can a transcription factor become oncogenic and transform a cell has not yet received an answer as far as Myb is concerned. Furthermore the state of the art is emblematic also for other oncogenic transcription factors including c-Myb. This objective is however of pivotal importance for the development of strategies to control neoplastic growth.
